EBITDA Margin % is calculated as EBITDA divided by its Revenue. Prostalund AB's EBITDA for the
three
months ended in Sep. 2025 was kr-2.62 Mil. Prostalund AB's Revenue for the
three
months ended in Sep. 2025 was kr2.23 Mil. Therefore, Prostalund AB's EBITDA margin for the quarter that ended in Sep. 2025 was -117.46%.
Prostalund AB (OSTO:PLUN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Prostalund AB EBITDA Margin % Related Terms
Prostalund AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Prostalund AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PLUN vs HCA, THC, UHS: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Prostalund AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostalund AB EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Prostalund AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Prostalund AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostalund AB (OSTO:PLUN) has a EBITDA Margin % of -117.46% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prostalund AB and its competitors.
Is Prostalund AB's EBITDA Margin % too high?
Prostalund AB's current EBITDA Margin % is -117.46%. Overall, Prostalund AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Prostalund AB's EBITDA Margin % compare to HCA and THC?
Prostalund AB's EBITDA Margin % of -117.46% can be compared against companies in the Healthcare Providers & Services industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prostalund AB and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostalund AB's current EBITDA Margin % is -117.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostalund AB stock overvalued right now?
Prostalund AB (OSTO:PLUN) has a current EBITDA Margin % of -117.46%. The stock's GF Value™ is kr8.60, compared to a current price of kr0.21 — trading 97.5% below its estimated fair value. The current EBITDA Margin % is -117.46%. Prostalund AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Prostalund AB (OSTO:PLUN), the current EBITDA Margin % is -117.46% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostalund AB (OSTO:PLUN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostalund AB stock appears to be undervalued.
The current stock price of kr0.21 is trading 97.5% below its estimated GF Value™ of kr8.60.
Key valuation signals for OSTO:PLUN:
EBITDA Margin %: -117.46%
GF Value™: kr8.60 vs. price of kr0.21 (97.5% below fair value)
No single metric tells the full story. See the OSTO:PLUN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostalund AB develops, markets and sells urological products. The Company has a treatment concept (CoreTherm Concept) for personalized heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50. It has developed a new platform, CoreTherm Eagle which includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians.
42GF Score
Get the complete analysis for OSTO:PLUN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PLUN has been successfully added to your 
